SPECTRE
Research type
Research Study
Full title
Combined Suppression Of Cholesterol Bioavailability And Androgen Deprivation Therapy To Treat Castration Resistant Prostate Cancer
IRAS ID
190773
Contact name
Hing Leung
Contact email
Sponsor organisation
NHS Greater Glasgow and Clyde
Eudract number
2015-003720-32
ISRCTN Number
ISRCTN16951765
Duration of Study in the UK
2 years, 11 months, 30 days
Research summary
The SPECTRE study will test the value of giving statins and hormone treatment at the same time to patients with hormone resistant prostate cancer.
Review (or retrospective evaluation) of previous published research on selected patient populations
has shown that individuals using statins after the initial diagnosis of prostate cancer tend to have lower risks of cancer recurrence following hormone manipulation treatment .
When patients on hormone treatment develop treatment resistance, the first sign will be a rise in the ‘PSA’ levels by blood test, these patients are often without any symptoms. In current practice, in the absence of any symptoms, these patients will be closely monitored. During this time, we will add statins to the ongoing hormone treatment that individuals are receiving.We intend to recruit 40 patients to the study. Patients will take the statin treatment daily, for a maximum of 6 weeks.
In addition, new tests in blood and prostate cancer tissue will be developed.
We also hope to obtain consent from 15 participating patients for undergoing needle prostate biopsies both before and after the addition of statins treatment. These samples will allow the research team to understand the importance of hormone production within the prostate tumours, including the proteins involved in making androgens as well as the products at various stages during the manufacturing process of male hormones.
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
16/EE/0110
Date of REC Opinion
1 Jun 2016
REC opinion
Further Information Favourable Opinion